Verve Therapeutics Revenue

Biotechnology Research • Boston, Massachusetts, United States • 201-500 Employees

Verve Therapeutics revenue & valuation

Annual revenue	$59,700,000
Revenue per employee	$271,000
Estimated valuation?This valuation is estimated based on industry average for the Biotechnology Research industry and current estimated revenues	$190,800,000
Total funding	$143,800,000

Key Contacts at Verve Therapeutics

Jill Wilson

Senior Director, Hrbp

Pratik Randeria

Director, Process Development

Corey Leonardi

Associate Director Clinical Operations

Kim Milliken

Executive Director Regulatory Cmc

Andrea Bartucca

Director, Patient Engagement And Recruitment

Emily Cronin

Director, Total Rewards

Julie Carchedi Downs

Director Corporate Communications

Florence Chan

Director, Human Resources Business Partner

Mike Maclean

Director

Poonam Shah

Associate Director- It Business Partner, G&A

Company overview

Headquarters	201 Brookline Ave, Suite 601, Boston, Massachusetts 02215, US
Phone number	+16176030070
Website	vervetx.com
NAICS	541714
SIC	873
Founded	2018
Employees	201-500
Socials

Verve Therapeutics Email Formats

Verve Therapeutics uses 4 email formats. The most common is {first initial}{last name} (e.g., jdoe@vervetx.com), used 92.4% of the time.

Format	Example	Percentage
{first initial}{last name}	jdoe@vervetx.com	92.4%
{first name}{last name}	johndoe@vervetx.com	3.2%
{last name}{last name}	doedoe@vervetx.com	2.5%
{last name}	doe@vervetx.com	1.3%

About Verve Therapeutics

Verve Therapeutics, a wholly owned subsidiary of Eli Lilly and Company, is developing a new class of genetic medicines for cardiovascular disease with the potential to transform treatment from chronic therapies to single-course gene editing medicines. The company's lead programs – VERVE-102, VERVE-201, and VERVE-301 – target the three lipoprotein drivers of atherosclerosis: low-density lipoproteins, triglyceride-rich lipoproteins, and lipoprotein(a). VERVE-102 is designed to permanently turn off the PCSK9 gene in the liver and is being developed initially for heterozygous familial hypercholesterolemia and ultimately to treat patients with established atherosclerotic cardiovascular disease (ASCVD) who continue to be impacted by high low-density lipoprotein cholesterol levels. VERVE-201 is designed to permanently turn off the ANGPTL3 gene in the liver and is initially being developed for refractory hypercholesterolemia, where patients still have high low-density lipoprotein cholesterol despite treatment with maximally tolerated standard of care therapies, and homozygous familial hypercholesterolemia. VERVE-301 is designed to permanently turn off the LPA gene to reduce lipoprotein (a) levels. Lipoprotein (a) is a genetically validated, independent risk factor for ASCVD, ischemic stroke, thrombosis, and aortic stenosis.

Employees by Management Level

Total employees: 201-500

Seniority

Employees

Director

Entry

Manager

Employees by Department

Verve Therapeutics has 79 employees across 11 departments.

Departments

Number of employees

Funding Data

Explore Verve Therapeutics's funding history, including investment rounds, total capital raised, and key backers.

Funding Date	Round	Amount	Link to Article
2023-12-28	14	$143,800,000

Funding Insights

$143,800,000

Total funding amount

$143,800,000

Most recent funding amount

Number of funding rounds

Verve Therapeutics Tech Stack

Discover the technologies and tools that power Verve Therapeutics's digital infrastructure, from frameworks to analytics platforms.

MariaDB

Databases

jQuery

JavaScript libraries

Google Tag Manager

Tag managers

GoDaddy

Hosting

Cookiebot

Cookie compliance

Nginx

Reverse proxies

Fastly

CDN

PHP

Programming languages

Pantheon

PaaS

HSTS

Security

Varnish

Caching

Cookie Control

Cookie compliance

Frequently asked questions

Verve Therapeutics is located in Boston, Massachusetts, US.

You can reach Verve Therapeutics at +16176030070.

Verve Therapeutics generates an estimated annual revenue of $59,613,000. This revenue figure reflects the company's market position and business performance in its industry.

Verve Therapeutics has an estimated valuation of $190,800,000. This valuation is calculated based on industry-standard revenue multiples and reflects the company's growth potential and market positioning.

Verve Therapeutics was founded in 2018, making it 8 years old. The company has established itself as a significant player in its industry over this time.

Verve Therapeutics has approximately 201-500 employees. The company continues to grow its workforce to support its business operations and expansion.

Verve Therapeutics has raised a total of $143,800,000 across 1 funding rounds. This investment has helped the company grow and expand its operations.